CD274 and neoplasm: The process leading to acquired resistance to anti-PD-1/PD-L1 therapy may entail the eventual degradation of T-cell function due to epigenetic dysfunction or the adoption of other immunosuppressive signals, an alteration in antigen presentation that lowers T-cell recognition of the tumor, and the development of resistance to the effects of interferon generated by T cells [96].